Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 79  
ORIGINAL ARTICLE
Year : 2012  |  Volume : 11  |  Issue : 3  |  Page : 105-109

Standard Operating Procedure for In-house Preparation of 131 I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma


Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle WA, Australia

Correspondence Address:
J Harvey Turner
Department of Nuclear Medicine, Fremantle Hospital, Fremantle WA
Australia
Login to access the Email id


DOI: 10.4103/1450-1147.103408

PMID: 23372447

Rights and Permissions

A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration of 131 I-rituximab appropriate for the safe, effective, radioimmunotherapy of non-Hodgkin lymphoma. A decade of experience of semi-automated radioiodination of rituximab in our hospital radiopharmaceutical laboratory was analysed. The methodology was then refined for safe, practical, affordable application to radioimmunotherapy of lymphoma in departments of nuclear medicine in developing countries. This SOP has the potential to be incorporated into good laboratory practice conditions appropriate for local regulatory agency requirements.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2860    
    Printed210    
    Emailed0    
    PDF Downloaded515    
    Comments [Add]    
    Cited by others 2    

Recommend this journal